A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

IGI reported that it has recently wrapped up the dose-escalation phase of its Phase 1 clinical trial involving patients with ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...